Table 3.
Multiple hypothesis testing of the association of gene SPAG5 with endocrine therapy and chemotherapy
| RFS | OS | DMFS | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Systemic therapy subtypes | |||||||||
| Endocrine therapy | 1.61 | 1.26–2.04 | < 0.001 | 1.95 | 1.47–2.60 | < 0.001 | 1.45 | 0.85–2.48 | ns,0.17 |
| Chemotherapy | 1.54 | 1.21–1.98 | < 0.001 | 1.57 | 1.16–2.12 | 0.0033 | 1.10 | 0.70–1.71 | ns,0.68 |
| Endo + chemo | 1.69 | 1.02–2.82 | ns,0.0428 | 1.67 | 1.01–2.80 | ns,0.051 | 0.99 | 0.34–2.86 | ns,0.988 |
ns Not significant after correction for multiple hypothesis testing, endo Endocrine therapy, chemo Chemotherapy